CELL INTELLIGENCE · 肿瘤细胞治疗研究

整合原位免疫表达图谱与基于基因表达的分型以刻画乳腺癌异质性

Integrating In Situ Immune Expression Landscape with Gene Expression-Based Subtyping to Characterize Breast Cancer Heterogeneity.

这些发现证实，部分 luminal 型肿瘤具有炎症性或巨噬细胞驱动的免疫微环境。

伊布替尼联合曲妥珠单抗治疗 HER2 阳性转移性乳腺癌的 I/II 期研究

A Phase I/II Study of Ibrutinib Plus Trastuzumab in HER2-Positive Metastatic Breast Cancer.

静息肥大细胞的转录特征与 HR(+)HER2(-) 乳腺癌疾病结局改善相关

A transcriptional signature of resting mast cells is associated with improved disease outcome in HR(+)HER2(-) breast cancer.

TIL（肿瘤浸润淋巴细胞）与促炎生物标志物同乳腺癌分子亚型的关联：MEND 研究分析

Association of tumor-infiltrating lymphocytes and proinflammatory biomarkers with breast cancer molecular subtypes: analysis of the MEND study.

尼日利亚女性中，TILs 升高和 TNF-主导型特征与 TNBC（相较于 ER+）相关，这突显了免疫治疗在尼日利亚 TNBC 病例中的潜在相关性，以及 TNF-可能的预后/治疗作用。

SACI-IO HR+：一项在转移性激素受体阳性/HER2 阴性乳腺癌患者中比较 sacituzumab govitecan 联合或不联合 pembrolizumab 的随机 II 期试验

SACI-IO HR+: a randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/

在未经 PD-L1 筛选的 HR 阳性/HER2 阴性 MBC 中，将帕博利珠单抗加入 SG 并未显著改善结局。在 PD-L1 阳性人群中，PFS 和 OS 倾向于支持 SG 联合帕博利珠单抗，值得在更大规模的随机试验中进一步研究。

体重指数与早期 HER2 阳性乳腺癌中 TIL（肿瘤浸润淋巴细胞）及治疗反应的关联

Association of Body Mass Index with Tumor-Infiltrating Lymphocytes and Treatment Response in Early HER2-Positive Breast Cancer.

以 BMI 反映的宿主相关因素可能影响早期 HER2 阳性乳腺癌的肿瘤免疫微环境以及免疫生物标志物的预测价值。

嵌合抗原受体自然杀伤（CAR-NK）细胞治疗乳腺癌的疗效与安全性评价：系统综述与荟萃分析

Evaluation of Efficacy and Safety of Chimeric Antigen Receptor-Natural Killer (CAR-NK) Cells in Breast Cancer: A Systematic Review and Meta-Analysis.

NSABP B-41 中早期 HER2 阳性乳腺癌 TIL（肿瘤浸润淋巴细胞）的 AI 驱动评估与人工评估

AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.

用 mRNA 治疗重编程三阴性乳腺癌的免疫微环境

Reprogramming the immune microenvironment in triple-negative breast cancer with mRNA therapeutics.

靶向三阴性乳腺癌的肿瘤微环境：单克隆抗体和免疫调节的新兴作用

Targeting the Tumor Microenvironment in Triple-Negative Breast Cancer: Emerging Roles of Monoclonal Antibodies and Immune Modulation.